INTRODUCTION {#s1}
============

Numerous studies reported expression levels of tissue \[[@R1]--[@R194]\] or blood \[[@R195]--[@R221]\] miRNAs were related with prognosis of HCC patients. HCC is one of the most common tumors, over 700,000 new cases are reported yearly, and HCC is considered as the third primary etiology of tumor-associated mortality rate globally \[[@R222]--[@R224]\]. In spite of enormous process in diagnosis and comprehensive therapy over the last few decades, HCC patients still have poor prognosis, primarily due to its high rate of recurrence \[[@R225]\] and metastasis \[[@R226]\].

miRNAs, a cluster of endogenous short non-coding single strand RNAs, serve as significant post-transcriptional regulatory factor of genetic expression via interacting with the 3′-UTR of the targeted mRNAs \[[@R227]\]. Conspicuously, due to widespread RNAase in the blood environment, circulating miRNAs displayed predominant stability. As a noninvasive detection method, circulating miRNA (blood) demonstrated more potential value as diagnostic and prognostic biomarkers than tissue miRNAs. Studies \[[@R228], [@R229]\] conducted in preclinical models and cancer patients proved that malignant tumor influences expression levels of miRNAs in the blood and that certain serum miRNAs are correlated with particular cancers. Though the way requires more validation, the finding possibly discloses the avenue to a creative method of detecting cancers via measurement of serum or plasma miRNAs.

Thus far, substantial investigations have discovered that miRNAs are involved and play a crucial role in the carcinogenesis of HCC \[[@R230], [@R231]\] while some miRNAs are up-regulated and others down-regulated in HCC. For example, Wong et al. \[[@R232]\] gained contrasting results that identifiable difference in miRNA expression pattern could not be discovered between primary HCC and venous metastases. However, comparing venous metastases to primary HCC, a prominent universal decrease of miRNA expression levels was assayed. Their results indicated that miRNA abnormality relatively early occured in liver carcinogenesis and the later universally decreased miRNA aggravated the preexisting miRNA abnormity to further accelerate HCC metastasis.

Nevertheless, there has not been a synthetic meta-analysis to assess precise prognostic value of miRNAs in HCC. As a consequence, it is of vital significance to develop a meta-analysis with an aim to evaluate it.

RESULTS {#s2}
=======

Study selection {#s2_1}
---------------

Figure [1](#F1){ref-type="fig"} showed a flow chart with details about the study selection process.

![Flow diagram of literature search and selection](oncotarget-08-107237-g001){#F1}

Study frequency {#s2_2}
---------------

Tables [1](#T1){ref-type="table"} (tissue) and [2](#T2){ref-type="table"} (blood) showed the frequency of researches evaluating prognostic value of miRNAs, including miRNA name, number of investigations assessing prognostic value, and reference.

###### Frequency of studies estimating prognostic value of tissue miRNA expression in hepatocellular carcinoma

  miR      N   R           miR      N   R            miR      N   R            miR        N   R              miR      N   R          miR       N   R
  -------- --- ----------- -------- --- ------------ -------- --- ------------ ---------- --- -------------- -------- --- ---------- --------- --- ----------
  1        1   1           29b      2   38, 39       125a     1   70           192        2   107, 108       330      1   143        520g      1   167
  7        1   2           29c      3   38, 40, 41   125b     2   71, 72       193a       1   29             331-3p   1   144        522       1   168
  9--1     2   3, 4        30a-5p   1   42           126      1   73           193b       1   29             338-3p   1   145        542-5p    1   169
  9--2     2   3, 4        30a      1   43           128-3p   1   74           194        1   109            339-5p   1   146        545       1   170
  9        3   5--7        30b-5p   1   44           129-5p   1   75           195        2   110, 111       365      1   147        589-5p    1   171
  10b      1   8           30b      1   9            129--2   1   76           197        1   112            370      1   148        592       1   172
  15a      1   9           30c      1   9            130a     1   77           199a-5p    2   11, 113        372      2   149, 150   608       1   173
  15b      1   9           30d      1   3            130b     1   78           199a^\*^   1   114            375      1   151        610       1   174
  17-5p    1   10          31       1   45           135a     2   18, 79       199a       1   114            381      1   9          622       1   175
  18a      1   11          33a-3p   1   46           137      2   80, 81       199b-5p    1   115            383      1   152        625       1   176
  18b      1   12          34a-5p   1   47           139-5p   1   82           200a       3   116--118       421      1   141        630       1   177
  19a      1   13          34a      3   48--50       139      1   83           203        3   119--121       424      2   141, 153   634       1   178
  19b      1   14          34b      2   50, 51       140-5p   1   84           204        1   107            425-3p   1   154        638       2   179, 180
  20a      2   15, 16      34c-3p   1   52           145      1   85           205        1   122            429      1   155        744       1   181
  20b      1   17          34c      2   50, 51       146a     1   86           210        2   123, 124       432      1   9          876-5p    1   9
  21a      1   18          92a      1   53           148a     3   87--89       211        1   125            451      1   156        885-5p    1   182
  21       8   2, 19--25   93       1   54           148b     2   90, 91       212        2   126, 127       452      1   157        892a      1   183
  22       3   4, 26, 27   98       1   55           149      2   92, 93       214        2   114, 128       454      1   158        940       2   184, 185
  23a      2   28, 29      99a      2   56, 57       150      1   95           216b       1   129            455      1   159        944       1   186
  23b      1   29          99b      1   58           151      1   96           218        1   130            486-3p   1   9          1180      1   187
  24       1   30          100      2   59, 60       152      1   97           219-5p     1   131            486-5p   1   160        1246      1   188
  25       2   31, 32      101      2   61, 62       155-3p   1   98           221        5   20, 132--135   489      1   161        1268a     1   189
  26a      1   33          103      1   2            155      3   9, 99, 100   222        1   136            494      1   162        1269      1   190
  26b-5p   1   34          105--1   1   63           182      1   101          224        1   137            497      1   163        1323      1   191
  27b      1   35          106b     2   64, 65       183      1   102          296        1   138            503      1   164        3127      1   192
  28-3p    1   36          107      1   2            185      1   103          302d       1   139            511--1   1   3          3677      2   3, 141
  28-5p    1   36          122      2   66, 67       187-3p   1   104          325        1   140            511--2   1   3          4458      1   193
  29a-5p   1   37          124--1   1   68           188-5p   1   105          326        2   3, 141         511      1   141        4782-3p   1   194
  29a      2   9, 38       124      1   69           191      1   106          329        1   142            519a     2   165, 166                 

Highlighted studies were included in the present meta-analysis; N: Number of studies estimating prognostic value; R: References.

###### Frequency of studies estimating prognostic value of blood miRNA expression in hepatocellular carcinoma

  miR      N   R                    miR       N   R          miR      N   R
  -------- --- -------------------- --------- --- ---------- -------- --- -----
  1        1   195                  139-5p    1   209        218      1   216
  10b-3p   1   196                  148a      2   208, 211   221      1   217
  21       4   197--200             148b      1   211        224-5p   1   198
  24-3p    1   201                  150       1   212        224      1   218
  26a      1   200                  152       1   211        311-3p   1   214
  29a-3p   1   202                  181a-5p   1   213        335      1   219
  29a      1   200                  182       1   214        422a     1   209
  96       1   203                  192-5p    1   202        424      1   220
  101      1   204                  192       1   208        486-5p   1   209
  122      6   195, 198, 205--208   200a      1   198        1246     1   208
  125b     1   209                  210       1   215        1290     1   208
  128-2    1   210                  215       1   208        4463     1   221

Highlighted studies were included in the present meta-analysis; N: Number of studies estimating prognostic value; R: References.

Study characteristics {#s2_3}
---------------------

[Supplementary Table 1](#SD2){ref-type="supplementary-material"} comprehensively presented the characteristics and details (names of miRNAs, information about the included articles, detected samples, sample size, stage, cut-off value, detection methods, follow-up, survival outcome with HR and 95% CI) of studies with Kaplan-Meier survival curves (K-M curves) in HCC. If the survival outcome was not furnished directly and merely as K-M curves, we used the software Engauge Digitizer version 4.1 \[[@R233]\] to extract the data from K-M curves. Additionally, if both the univariate and multivariate outcomes were covered, we just chose the latter in that the confounding factors were corrected.

Meta-analysis {#s2_4}
-------------

Table [3](#T3){ref-type="table"} presented a summary of the HR estimated from pooled analysis for the included miRNAs. A total of 16 miRNAs were screened by our present study.

###### Summary of the HR for miRNA expression in hepatocellular carcinoma

  ------------------------------------------------------------------------------------------------------------------------------------------------
  miRNA          Survival\     Number\       Included\            HR     95% CI        Figure   *P* value   Heterogeneity\              Total\
                 analysis      of articles   studies                                                        (Higgins I^2^ statistic)    patients
  -------------- ------------- ------------- -------------------- ------ ------------- -------- ----------- --------------------------- ----------
  High miR-9     OS            2             5, 7                 2.35   1.46--3.76    4        \< 0.01     I^2^ = 35.3%, *P =* 0.21    320

  High miR-9     DFS/RFS       2             6,7                  2.49   1.57--3.97    4        \< 0.01     I^2^ = 0.0%, *P =* 0.80     180

  High miR-21    OS            6             19, 20, 22--25       1.76   1.29--2.41    2A       \< 0.01     I^2^ = 17.1%, *P =* 0.30    461

  High miR-21    DFS           3             2, 21, 22            3.48   1.89--6.44    2A       \< 0.01     I^2^ = 40.4%, *P =* 0.19    274

  High miR-21    OS^m^         2             22, 23               2.72   1.49--4.95    2A       \< 0.01     I^2^ = 0.0%, *P =* 0.58     231

  High miR-21    RFS/DFS       2             197, 200             1.11   0.62--1.96    7        0.73        I^2^ = 72.7%, *P =* 0.06    246

  High miR-21    OS            2             198, 199             1.73   1.07--2.80    7        0.03        I^2^ = 59.0%, *P =* 0.12    233

  Low miR-22     OS            2             4, 27                2.29   1.63--3.21    4        \< 0.01     I^2^ = 0.0%, *P =* 0.85     564

  Low miR-29a    OS            3             9, 37, 38            1.29   0.91--1.81    4        0.15        I^2^ = 47.8%, *P =* 0.15    657

  Low miR-29a    RFS           2             9, 37                0.82   0.38--1.77    4        0.61        I^2^ = 83.0%, *P =* 0.02    434

  High miR-29a   PFS/DFS       2             200, 202             1.12   0.32--3.94    7        0.86        I^2^ = 89.1%, *P* \< 0.01   194

  Low miR-29c    OS            3             38, 40, 41           1.35   1.10--1.65    4        \< 0.01     I^2^ = 0.0%, *P =* 0.47     467

  Low miR-34a    OS            4             47--50               1.84   1.30--2.59    5        \< 0.01     I^2^ = 48.7%, *P =* 0.12    339

  Low miR-34a    PFS/RFS/DFS   3             47, 49, 50           1.43   1.17--1.74    5        \< 0.01     I^2^ = 20.3%, *P =* 0.29    309

  High miR-34c   OS            2             50, 52               1.64   1.05--2.57    5        0.03        I^2^ = 0.0%, *P =* 0.41     156

  High miR-34c   DFS           3             50--52               1.15   0.72--1.85    5        0.56        I^2^ = 72.5%, *P =* 0.03    236

  High miR-122   OS            6             195, 198, 205--208   0.89   0.49--1.60    3A       0.69        I^2^ = 84.8%, *P* \< 0.01   896

  High miR-122   DFS           2             205, 208             1.62   0.40--6.41    3A       0.50        I^2^ = 50.6%, *P =* 0.16    182

  Low miR-148a   OS            2             87, 88               1.83   0.80--4.20    5        0.15        I^2^ = 67.2%, *P* \< 0.05   356

  Low miR-148a   RFS           3             87--89               1.37   0.99--1.91    5        0.06        I^2^ = 0.0%, *P =* 0.55     445

  Low miR-148a   OS            2             208, 211             2.26   1.11--4.59    7        0.03        I^2^ = 0.0%, *P =* 0.99     138

  High miR-155   OS            3             98--100              2.84   1.46--5.51    5        \< 0.01     I^2^ = 57.8%, *P =* 0.09    269

  High miR-155   RFS/DFS       3             9, 99, 100           2.09   1.56--2.79    5        \< 0.01     I^2^ = 0.0%, *P =* 0.66     440

  High miR-192   OS            2             202, 208             2.42   1.15--5.10    7        0.02        I^2^ = 6.7%, *P =* 0.30     136

  High miR-192   PFS/DFS       2             202, 208             1.97   0.96--4.03    7        0.06        I^2^ = 2.5%, *P =* 0.31     136

  Low miR-199a   OS            2             113, 114             2.78   1.89--4.08    6        \< 0.01     I^2^ = 0.0%, *P =* 0.38     239

  Low miR-200a   OS            3             116--118             2.64   1.86--3.77    6        \< 0.01     I^2^ = 0.0%, *P =* 0.91     336

  Low miR-203    OS            2             119, 121             2.20   1.61--3.00    6        \< 0.01     I^2^ = 0.0%, *P =* 0.45     204

  Low miR-203    RFS           2             119, 120             2.12   0.40--11.16   6        0.37        I^2^ = 76.1%, *P =* 0.04    161

  High miR-221   OS            3             20, 132, 135         1.76   1.02--3.04    6        0.04        I^2^ = 67.6%, *P* \< 0.05   240

  High miR-221   RFS/MFS/DFS   4             132--135             2.26   1.53--3.35    6        \< 0.01     I^2^ = 50.4%, *P =* 0.09    334

  High miR-224   OS            2             198, 218             1.56   1.14--2.12    7        \< 0.01     I^2^ = 24.2%, *P =* 0.25    318
  ------------------------------------------------------------------------------------------------------------------------------------------------

HR: hazard ratios; CI: confidence intervals; OS: overall survival; DFS: disease-free survival; RFS: recurrence-free survival; PFS: progression-free survival; MFS: metastasis-free survival; ^m^Multivariate analysis.

Significantly prognostic value of high tissue miR-21 expression in OS {#s2_5}
---------------------------------------------------------------------

Six studies \[[@R19], [@R20], [@R22]--[@R25]\] focused on the correlation between high tissue miR-21 level and OS, suggesting that HCC patients with high tissue miR-21 level demonstrated a significantly worse OS than those with low tissue miR-21 level (HR = 1.76, 95% CI = 1.29--2.41, *P* \< 0.01, Figure [2A](#F2){ref-type="fig"}).

![(**A**) Forest plot of the analyses about high expression of tissue miR-21 and OS, DFS or OS (multivariate analysis); (**B**) Publication bias of the analysis about high expression of tissue miR-21 and OS and (**C**) Sensitivity analysis of the study about high expression of tissue miR-21 and OS.](oncotarget-08-107237-g002){#F2}

Publication bias {#s2_6}
----------------

For the purpose of evaluating publication bias on OS of HCC patients with high tissue miR-21 level, we employed the Begg's funnel plot (Figure [2B](#F2){ref-type="fig"}). Accordingly, the *P* value was 0.21, suggesting nonexistent publication bias.

Sensitivity analysis {#s2_7}
--------------------

The sensitivity analysis did not manifest variances among the outcomes in terms of the exclusion of any single research (Figure [2C](#F2){ref-type="fig"}) in the estimation on OS of HCC patients with high tissue miR-21 level, indicating that no individual investigation significantly affected the merged HR with 95% CI.

No significantly prognostic value of high blood miR-122 expression in OS {#s2_8}
------------------------------------------------------------------------

Six researches \[[@R1], [@R4], [@R11]--[@R14]\] concentrated on the relationship between high blood miR-122 level and OS, manifesting that there was no significant correlation between high blood miR-122 level and OS (HR = 0.89, 95% CI = 0.49--1.60, *P* = 0.69, Figure [3A](#F3){ref-type="fig"}).

![(**A**) Forest plot of the analyses about high expression of blood miR-122 and OS or DFS; (**B**) Publication bias of the analysis about high expression of blood miR-122 and OS and (**C**) Sensitivity analysis of the study about high expression of blood miR-122 and OS.](oncotarget-08-107237-g003){#F3}

Publication bias {#s2_9}
----------------

For the sake of estimating publication bias on OS of HCC patients with high blood miR-122 level, we employed the Begg's funnel plot (Figure [3B](#F3){ref-type="fig"}). Consequently, the *P* value was 0.56, suggesting nonexistent publication bias.

Sensitivity analysis {#s2_10}
--------------------

The sensitivity analysis did not manifest variances among the outcomes in terms of the exclusion of any single research (Figure [3C](#F3){ref-type="fig"}) in the estimation on OS of HCC patients with high blood miR-122 level, indicating that no individual investigation significantly affected the merged HR with 95% CI.

Meta-regression {#s2_11}
---------------

We employed the meta-regression to seek source of heterogeneity (I^2^ = 84.8%) on OS of HCC patients with high blood miR-122 level. The details were shown in Table [4](#T4){ref-type="table"}, and source of heterogeneity was significantly caused by maximum months of follow-up (*P* = 0.01).

###### Results of meta-regression on OS of blood miR-122 expression in hepatocellular carcinoma

  Variables   Details                       tau^2^   I^2^ (%)   Adj R^2^ (%)   *P* value
  ----------- ----------------------------- -------- ---------- -------------- -----------
  Year        2013--2016                    0.73     87.82      --29.29        0.46
  Country     Germany, China, South Korea   0.50     86.34      11.27          0.34
  Design      Prospective, Retrospective    0.61     88.00      --21.49        0.51
  Sample      Serum, Plasma                 0.45     87.43      20.85          0.16
  Number      295, 136, 120, 122, 161, 62   0.69     86.03      --21.90        0.47
  Stage       None, I--IV                   0.52     87.59      8.14           0.39
  Method      qRT-PCR, RT-qPCR              0.51     87.01      10.36          0.22
  Follow-up   26, 48, 96, 40, 79, 125       0.28     84.28      50.82          0.08
  Follow-up   \< 48, ≥ 48                   0.00     9.67       100.00         0.01

Tissue miR-9, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 have significantly prognostic values in OS {#s2_12}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} and Figures [4](#F4){ref-type="fig"}--[7](#F7){ref-type="fig"} showed the details.

![Forest plot of the analyses about high expression of tissue miR-9 or low expression of tissue miR-22, 29a, 29c and OS, DFS/RFS or RFS](oncotarget-08-107237-g004){#F4}

![Forest plot of the analyses about high expression of tissue miR-34c, 155 or low expression of tissue miR-34a, 148a and OS, PFS/RFS/DFS, DFS, RFS or RFS/DFS](oncotarget-08-107237-g005){#F5}

![Forest plot of the analyses about high expression of tissue miR-221 or low expression of tissue miR-199a, 200a, 203 and OS, RFS or RFS/MFS/DFS](oncotarget-08-107237-g006){#F6}

![Forest plot of the analyses about high expression of blood miR-21, 29a, 192, 224 or low expression of blood miR-148a and RFS/DFS, OS or PFS/DFS](oncotarget-08-107237-g007){#F7}

Tissue miR-29a, miR-148a and blood miR-29a do not have significantly prognostic values in OS {#s2_13}
--------------------------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} and Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"} and [7](#F7){ref-type="fig"} showed the details.

DISCUSSION {#s3}
==========

Status quo {#s3_1}
----------

Numerous articles reported that dysregulated expression levels of miRNAs correlated with survival time of HCC patients \[[@R1]--[@R221]\]. Nevertheless, there has not been a comprehensive meta-analysis to assess the accurate prognostic value of miRNAs in HCC. Therefore, it was conducted to estimate the relationship between dysregulated miRNA level and survival time of HCC patients.

Main discoveries {#s3_2}
----------------

For HCC patients, tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value (*P* \< 0.05). In the light of our reference standard, tissue miR-9, miR-22, miR-155, miR-199a, miR-200a, miR-203 and blood miR-148a, miR-192 potential prognostic candidates for predicting the OS of HCC patients (HR ≥ 2).

Molecular mechanisms for included miRNAs {#s3_3}
----------------------------------------

For included miRNAs in the current study, a summary of miRNAs with changed levels, their possible targets and pathways enrolled in the present study has been presented in Table [5](#T5){ref-type="table"}. From the data of the table, these potential targets and pathways may be involved with survival outcome of HCC patients.

###### Summary of miRNAs with altered expression, their potential targets and pathways entered this study

  miRNA   Reference             Expression   Potential target           Pathway
  ------- --------------------- ------------ -------------------------- ------------------------------------------------------------------------------------------
  9       5--7                  Up           GALNT4                     None
  21      2, 19--25, 197--200   Up           None                       None
  22      4, 26, 27             Down         YWHAZ, HDAC4               Cell invasion, migration, proliferation, tumourigenicity and YWHAZ/AKT1/foxo3a signaling
  29a     9, 37, 38, 200, 202   Up           None                       None
  29c     38, 40, 41            Down         SIRT1                      None
  34a     47--50                Down         FOXM1, MYC, BCL2, AXL      Cell apoptosis, chemoresistance, proliferation, viability and FOXM1/MYC signaling
  34c     50--52                Down         NCKAP1                     Cell cycle, growth, invasion and proliferation
  122     195, 198, 205--208    None         None                       None
  148a    87-89, 208, 211       Down         USP4, SIP1                 Cell invasion, migration and proliferation
  155     9, 98--100            Up           ARID2, FBXW7               Cell apoptosis, cycle, invasion, proliferation and tumorigenesis
  192     202, 208              Up           None                       None
  199a    11, 113, 114          Down         HIF1A, VEGFA, IGF1, IGF2   Cell growth, invasion, proliferation and Warburg effect
  200a    116-118               Down         MACC1, CDK6, ZEB2          Cell cycle, growth, metastasis and proliferation
  203     119--121              Down         ADAM9, HULC                Cell apoptosis, invasion and proliferation
  221     20, 132--135          Up           Bmf                        Cell apoptosis and growth
  224     198, 218              None         None                       None

GALNT4: polypeptide N-acetylgalacosaminyltransferase 4; YWHAZ: tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta; HDAC4: histone deacetylase 4; AKT1: AKT serine/threonine kinase 1; foxo3a: forkhead box O3A; SIRT1: sirtuin 1; FOXM1: forkhead box M1; MYC: MYC proto-oncogene, bHLH transcription factor; BCL2: BCL2, apoptosis regulator; AXL: AXL receptor tyrosine kinase; NCKAP1: NCK associated protein 1; USP4: ubiquitin specific peptidase 4; SIP1: Sip1p; ARID2: AT-rich interaction domain 2; FBXW7: F-box and WD repeat domain containing 7; HIF1A: hypoxia inducible factor 1 alpha subunit; VEGFA: vascular endothelial growth factor A; IGF1: insulin like growth factor 1; IGF2: insulin like growth factor 2; MACC1: MACC1, MET transcriptional regulator; CDK6: cyclin dependent kinase 6; ZEB2: zinc finger E-box binding homeobox 2; ADAM9: ADAM metallopeptidase domain 9; HULC: hepatocellular carcinoma up-regulated long non-coding RNA; BMF: Bcl2 modifying factor.

Strengths of the meta-analysis {#s3_4}
------------------------------

There are a few strengths in this study, which are as follows: (1) nearly all articles estimating associations between miRNA level and survival result of HCC patients are shown in the current meta-analysis; (2) the number about HCC patients of all researches included in this study are more than or equal to 30, which makes the meta-analyses more convincing; (3) the Begg's funnel plot and sensitivity analysis were used for miR-21 and miR-122, which excluded publication bias and excessive influence of individual study; (4) we employed meta-regression to seek source of heterogeneity, which indicated that months of follow-up were significantly associated with it; (5) studies merely proposing HR or 95% CI without K-M curves were excluded.

Limitations {#s3_5}
-----------

Simultaneously, there are also limitations for the current work: (1) only English articles were included by us, which possibly excluded some studies written in other languages; (2) not all the articles assessing associations between miRNA level and survival time were included in the present study, which might neglect some potential miRNAs; (3) a few variables emerged among the included investigations, including different kinds of samples from HCC patients at different stages, cut-off values and detection methods, and only random-effects models were employed for all meta-analyses; (4) although overall studies included 54 relevant articles and 6464 patients in the present study, the number of articles and patients may be not enough for 16 miRNAs focused on.

Implications for future clinical and scientific research {#s3_6}
--------------------------------------------------------

With expression profiles shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, we can conveniently find relevant article about a single miRNA. Thus, the present study tendency for miRNAs in HCC can be easily obtained by basic researchers. Meanwhile, combined detection of multi-miRNAs can greatly increase the predict level for HCC patients. Besides, for clinical doctors, combined use of tissue and blood from HCC patients can bring about synergistic effect to estimation of prognosis.

MATERIALS AND METHODS {#s4}
=====================

Search strategy, inclusion criteria and exclusion criteria {#s4_1}
----------------------------------------------------------

The details were presented in Table [6](#T6){ref-type="table"}. Two authors (Yue Zhang and Chao Wei) independently performed this comprehensive online search.

###### Information of search methods and criteria of inclusion and exclusion

  -----------------------------------------------------------------------------------
  Methods              Information
  -------------------- --------------------------------------------------------------
  Search strategy      4 search engines, including PubMed, EMBASE, Web of\
                       Science and Cochrane Database of Systematic Reviews

  Search deadline      15 April, 2017

  Search terms         mir and hepatocellular carcinoma

  Inclusion criteria   \(1\) Patients with hepatocellular carcinoma;\
                       (2) Expression of miRNAs and survival outcome in\
                       tissue, plasma or serum were measured;\
                       (3) At least, one of survival curves about overall survival\
                       (OS), cause-specific survival (CSS), disease-free survival\
                       (DFS), recurrence-free survival (RFS), progression-free\
                       survival (PFS) and metastasis-free survival (MFS)\
                       was measured, with or without the HR or 95% CI;\
                       (4) Full text articles published in English

  Exclusion criteria   \(1\) Reviews, letters or laboratory studies without\
                       original data and retracted articles;\
                       (2) Frequency of studies estimating prognostic value\
                       of miRNAs ≤ 2 in tissue;\
                       (3) Studies which cannot be merged;\
                       (4) If more than one article had been published on the\
                       identical study cohort, only the most comprehensive\
                       study was selected for the present meta-analysis
  -----------------------------------------------------------------------------------

Quality assessment {#s4_2}
------------------

Yue Zhang and Chao Wei confirmed all eligible investigations that analyzed the prognostic value of miRNAs in HCC, and Yue-Hua Jiang reassessed uncertain data.

Statistical analysis {#s4_3}
--------------------

All analyses were conducted using Stata version 13.0 (StataCorp, College Station, Texas, USA). The relative effect sizes for HR were characterized as moderate (protective \[0.51--0.75\] or contributory \[1.35--1.99\]) and large (≤ 0.50 or ≥ 2). The HR was considered significant at the *P* \< 0.05 level if the 95% CI did not include the value 1. If the *P* values from OS and other survival results about corresponding miRNAs were inconsistent, the HR from OS was considered to the main reference standard. Because different types of samples (tissue, plasma and serum) from HCC patients at different disease stages, cut-off values and miRNA methods were used in individual studies, random-effects models (DerSimonian-Laird method) were more appropriate than fixed-models (Mantel-Haenszel method) for most of the analyses. Consequently, the random-effects models were used in the current meta-analysis. Source of heterogeneity was explored through meta-regression. Publication bias was estimated using the Begg's funnel plot. A two-tailed *P* value \< 0.05 was considered significant. Sensitivity analysis (influence analysis) was carried out to test how powerful the combined effect size was to removal of individual investigation. If the point assessment was out of the 95% CI of the pooled effect size after it was removed from the analysis, an individual study was doubted to have excessive influence.

CONCLUSIONS {#s5}
===========

In conclusion, tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value. Among them, tissue miR-9, miR-22, miR-155, miR-199a, miR-200a, miR-203 and blood miR-148a, miR-192 are potential prognostic candidates for predicting OS in HCC.
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